Navigation Links
NeurogesX to Present at Roth 2008 OC Growth Stock Conference
Date:2/19/2008

believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Steph
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
2. NeurogesX Closes $25 Million Private Placement
3. NeurogesX, Inc. Announces $25 Million Private Placement
4. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX Expands Senior Management Team
7. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
8. NeurogesX Appoints New Director to the Board
9. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  UBM Medica US announces that ... community to help oncologists and other clinicians gain ... regarding the use of targeted therapies and immunotherapies, ... March is National Kidney Cancer Awareness Month ... treatment options for renal cell carcinoma (RCC) patients. ...
(Date:3/5/2015)... March 05, 2015 e2b teknologies ... Partner located in Northeast Ohio, today announced a leading ... to support its upgrade to the latest version of ... independent group practice of its kind in the region, ... volume of transactions, so efficiency and data accessibility are ...
(Date:3/4/2015)... , March 4, 2015 PDL BioPharma, Inc. (PDL) ... conversion rate for the: , 3.75% Convertible Senior ... shares of common stock per $1,000 principal amount or approximately ... conversion rate for the note is adjusted in connection with ... March 12, 2015, to all stockholders who own shares of PDL ...
(Date:3/4/2015)...  Brooklyn residents now have a new place to ... injuries. Nunzio Saulle , M.D., a board-certified physiatrist, ... NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 2015. Health Plus Management, LLC is managing the day-to-day ... Flatbush Avenue. This new PM&R practice will treat patients ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... March 13 Varian Medical Systems (NYSE: VAR ... the non-destructive testing market at the upcoming ASNT Research Symposium ... Millennium Hotel in St. Louis, MO.The company will exhibit a ... , ...
... Technology (TU/e) have for the first time made ... formation. They used the world,s most advanced electron ... that are at the heart of the process. ... and shell formation. For industrial applications, they promise ...
... Call on Friday, March 13, 2009 at 8:30am ... Inc. (Nasdaq: KERX ), a biopharmaceutical ... of medically important, novel pharmaceutical products for the ... cancer (the "Company"), today announced its results for ...
Cached Biology Technology:Varian Medical Systems to Exhibit X-ray and CT Technologies for Non-Destructive Testing at the Upcoming ASNT 18th Annual Spring Conference 2First high-resolution images of bone, tooth and shell formation 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 6
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:2/25/2015)... ROCK, Ark. , Feb. 25, 2015 /PRNewswire/ ... software and billing in the Health and Fitness ... as well as to MYiCLUBonline.  The latest upgrade ... and the inclusion of cardless check-in via Identity ... for the first time through interactive displays at ...
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... University of Guelph researchers has proven up to 88 ... to a new U of G study. The ... Research International . It,s a crucial finding because ... poses economic, health, legal and environmental implications, says study ...
... New Rochelle, NY, September 19, 2012-- Researchers have successfully ... from mice that can be grown in large quantities ... develop into many different cell types needed throughout the ... cell biology and human development and disease is described ...
... KNOXVILLEShoppers particularly women who take the time ... don,t. These findings are from a recently released ... Tennessee professor in the Institute of Agriculture,s Department of ... the University of Santiago de Compostela in Spain, the ...
Cached Biology News:Study: DNA barcoding can ID natural health products 2
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... recombinant human protein produced in E. coli and ... A type enzymes. The mode of inhibition ... a 1:1 ratio. The enzyme has been shown ... cell types. Addition of the ribonuclease inhibitor has ...
Biology Products: